In recent years, new immunotherapy drugs inhibiting the interaction between programmed death 1 (PD-1) expressed on T-helper lymphocytes and its ligand programmed death-ligand-1 (PD-L1) expressed on cancer cells have been utilized as an effective treatment for different types of advanced cancers including HNSCC. This evidence concerns the gene CD274 and cancer.